SCYNEXIS Inc (135A F) stock market data APIs
€0.6843
0(0%)
as of May 21, 2025
Try our APIs with
free plan!
SCYNEXIS Inc Financial Data Overview
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, CJSC (R-Pharm), and Cypralis Limited for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Prev. Close
0.6843
Open
0.6843
High
0.6843
Low
0.6843
52 wk Range
0.683-2.24
Market Cap
25 870 K
Shares Outstanding
39 020 K
Revenue
3 746 K
Beta
1.655
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get SCYNEXIS Inc data using free add-ons & libraries
Get SCYNEXIS Inc Fundamental Data
SCYNEXIS Inc Fundamental data includes:
- Net Revenue: 3 746 K
- EBITDA: -36 537 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-06
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
SCYNEXIS Inc News
New
SCYNEXIS and Hansoh Pharma Announce NMPA Acceptance of the New Drug Application for Ibrexafungerp in China
Scynexis JERSEY CITY, N.J., July 20, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and dru...
Deadly Fungi Are Becoming More Common And We’re Running Out of Ways to Treat Them
As certain fungi such as Candida auris become more widespread throughout the U.S., deaths related to severe fungal infections are rising. WSJ’s Daniela Hernandez explains what you should know. Dangerous fungi are advancing faster than drugs to contain them.
Doctors Desperately Need Drugs to Kill Deadly Fungi. It’s an Uphill Fight.
As certain fungi such as Candida auris become more widespread throughout the U.S., deaths related to severe fungal infections are rising. WSJ’s Daniela Hernandez explains what you should know. Dangerous fungi are advancing faster than drugs to contain them.
SCYNEXIS Announces Achievement of First Development Milestone of $25 Million Under Exclusive License Agreement with GSK
Scynexis JERSEY CITY, N.J., June 21, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and dru...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
